4-Bromomethylbenzoic acid r-butyl ester | 86582-55-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Bromomethylbenzoic acid r-butyl ester
• 英文别名: p-bromomethylbenzoic acid-n-butyl ester；butyl 4-(bromomethyl)benzoate
• CAS: 86582-55-0
• 化学式: C₁₂H₁₅BrO₂
• 分子量: 271.154
• InChiKey: HUHMXYOWQLTPGG-UHFFFAOYSA-N

物化性质

• 沸点：
  333.0±25.0 °C(Predicted)
• 密度：
  1.314±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-Bromomethylbenzoic acid r-butyl ester 在 sodium hydroxide 作用下， 以 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 16.5h， 生成 butyl 4-((E)-4-((E)-2-(4-pyridinyl)vinyl)styryl)benzoate
  参考文献：
  名称：

  Anti-oligomerization sheet molecules: Design, synthesis and evaluation of inhibitory activities against α-synuclein aggregation

  摘要：

  Aggregation of alpha-synuclein (alpha-Syn) play a key role in the development of Parkinson Disease (PD). One of the effective approaches is to stabilize the native, monomeric protein with suitable molecule ligands. We have designed and synthesized a series of sheet-like conjugated compounds which possess different skeletons and various heteroatoms in the two blocks located at both ends of linker, which have good pi-electron delocalization and high ability of hydrogen-bond formation. They have shown anti-aggregation activities in vitro towards alpha-Syn with IC50 down to 1.09 mu M. The molecule is found binding in parallel to the NACore within NAC domain of alpha-Syn, interfering aggregation of NAC region within different alpha-Syn monomer, and further inhibiting or slowing down the formation of alpha-Syn oligomer nuclei at lag phase. The potential inhibitor obtained by our strategy is considered to be highly efficient to inhibit alpha-Syn aggregation.

  DOI：

  10.1016/j.bmc.2019.05.032
• 作为产物：
  描述：

  4-甲基-苯甲酸丁酯 在 N-溴代丁二酰亚胺(NBS) 、 过氧化氢苯甲酰 作用下， 以 四氯化碳 为溶剂， 反应 12.0h， 生成 4-Bromomethylbenzoic acid r-butyl ester
  参考文献：
  名称：

  设计，合成和生物学评估新型三唑衍生物作为细胞色素P45014α-脱甲基酶的抑制剂

  摘要：

  基于对接至细胞色素P45014α-脱甲基酶（CYP51）活性位点的计算结果，一系列1-（1 H -1,2,4-三唑-1-基）-2-（2,4设计，合成并评价了作为氟康唑类似物的-（二氟苯基）-3-取代-2-丙醇作为抗真菌剂。MIC 80值表明，化合物1a – n对除烟曲霉以外的几乎所有测试真菌均显示出比氟康唑更高的活性，而化合物2a – f，3a – f对所有测试真菌均无活性或仅有中等活性。值得注意的是，化合物的MIC值1A，1b和1g比氟康唑体外抗小孢子石膏的含量低64倍。化合物1a，1b和2b的抗白念珠菌活性（氟康唑的MIC 80值为0.0039μg/ mL）是其128倍，并且其活性也高于其他阳性对照。计算对接实验表明，CYP51的抑制作用涉及与血红素基团的铁，亲水性H键区，疏水性区和窄的疏水性裂口的配位键。另外，当侧链较短时，化合物的活性将增强。

  DOI：

  10.1016/j.ejmech.2008.11.007

文献信息

• [EN] PYRIDO [3,4-D] PYRIMIDINE DERIVATIVES AS MATRIX METALLOPROTEINASE-13 INHIBITORS<br/>[FR] DERIVES DE PYRIDO[3,4-D]PYRIMIDINE UTILES COMME INHIBITEURS DE LA METALLOPROTEINASE-13 DE MATRICE
  申请人：WARNER LAMBERT CO

  公开号：WO2005016926A1

  公开（公告）日：2005-02-24

  This invention relates to a pyrido[3,4-d]pyrimidine derivative of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R, L', L2, V, L3, and R2 are as defined in the specification, that inhibits a matrix metalloproteinase-13 enzyme and thus is useful for treating diseases resulting from MMP-13 mediated tissue breakdown such as osteoarthritis, rheumatoid arthritis, cartilage damage, psoriatic arthritis, ankylosing spondylitis, heart failure, atherosclerosis, inflammatory bowel disease, multiple sclerosis, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, cancer, and osteoporosis.

  该发明涉及一种Formula (I)的吡啶并[3,4-d]嘧啶衍生物，或其药用可接受盐，其中R、L'、L2、V、L3和R2如规范中所定义，该衍生物抑制基质金属蛋白酶-13酶，因此可用于治疗由MMP-13介导的组织分解引起的疾病，如骨关节炎、类风湿性关节炎、软骨损伤、银屑病性关节炎、强直性脊柱炎、心力衰竭、动脉粥样硬化、炎性肠病、多发性硬化、年龄相关性黄斑变性、慢性阻塞性肺疾病、哮喘、牙周疾病、银屑病、癌症和骨质疏松症。
• Antitumor agent, novel 3(2H)-pyridazinone derivatives and their preparation
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0665223A1

  公开（公告）日：1995-08-02

  Anti-tomor agents comprising novel 3(2H)-pyridazinone derivatives or salts thereof and methods of producing the same are disclosed. Also disclosed is a method for treating or preventing tumors by administering to a mammal a therapeutically effective amount of 4,5-di substituted 3(2H)-pyridazinones and salts thereof.

  本发明公开了包含新型3(2H)-吡啶嗪酮衍生物或其盐的抗肿瘤剂和其制备方法。同时还公开了一种通过向哺乳动物施用治疗有效量的4,5-二取代3(2H)-吡啶嗪酮及其盐来治疗或预防肿瘤的方法。
• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Abelman Matthew

  公开号：US20100113514A1

  公开（公告）日：2010-05-06

  The present invention relates to sodium channel inhibitors of Formula : in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are as defined above, and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes.

  本发明涉及一种公式化合物的钠通道抑制剂：其中R1，R2，R3，R4，R5，R6和R7如上所定义，并且涉及它们在治疗各种疾病状态中的使用，包括心血管疾病和糖尿病。
• Anti-oligomerization sheet molecules: Design, synthesis and evaluation of inhibitory activities against α-synuclein aggregation
  作者：Hao Liu、Li Chen、Fei Zhou、Yun-Xiao Zhang、Ji Xu、Meng Xu、Su-Ping Bai

  DOI：10.1016/j.bmc.2019.05.032

  日期：2019.7

  Aggregation of alpha-synuclein (alpha-Syn) play a key role in the development of Parkinson Disease (PD). One of the effective approaches is to stabilize the native, monomeric protein with suitable molecule ligands. We have designed and synthesized a series of sheet-like conjugated compounds which possess different skeletons and various heteroatoms in the two blocks located at both ends of linker, which have good pi-electron delocalization and high ability of hydrogen-bond formation. They have shown anti-aggregation activities in vitro towards alpha-Syn with IC50 down to 1.09 mu M. The molecule is found binding in parallel to the NACore within NAC domain of alpha-Syn, interfering aggregation of NAC region within different alpha-Syn monomer, and further inhibiting or slowing down the formation of alpha-Syn oligomer nuclei at lag phase. The potential inhibitor obtained by our strategy is considered to be highly efficient to inhibit alpha-Syn aggregation.
• Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14α-demethylase
  作者：Xiaoyun Chai、Jun Zhang、Honggang Hu、Shichong Yu、Qingyan Sun、Zhigang Dan、Yuanying Jiang、Qiuye Wu

  DOI：10.1016/j.ejmech.2008.11.007

  日期：2009.5

  Based on the results of computational docking to the active site of the cytochrome P450 14α-demethylase (CYP51), a series of 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted-2-propanols as analogs of fluconazole were designed, synthesized, and evaluated as antifungal agents. The MIC80 values indicate that compounds 1a–n exhibited higher activity against nearly all fungi tested except

  基于对接至细胞色素P45014α-脱甲基酶（CYP51）活性位点的计算结果，一系列1-（1 H -1,2,4-三唑-1-基）-2-（2,4设计，合成并评价了作为氟康唑类似物的-（二氟苯基）-3-取代-2-丙醇作为抗真菌剂。MIC 80值表明，化合物1a – n对除烟曲霉以外的几乎所有测试真菌均显示出比氟康唑更高的活性，而化合物2a – f，3a – f对所有测试真菌均无活性或仅有中等活性。值得注意的是，化合物的MIC值1A，1b和1g比氟康唑体外抗小孢子石膏的含量低64倍。化合物1a，1b和2b的抗白念珠菌活性（氟康唑的MIC 80值为0.0039μg/ mL）是其128倍，并且其活性也高于其他阳性对照。计算对接实验表明，CYP51的抑制作用涉及与血红素基团的铁，亲水性H键区，疏水性区和窄的疏水性裂口的配位键。另外，当侧链较短时，化合物的活性将增强。